Progression-Free Survival Endpoint Not Reached in Abituzumab Study
the Cancer Therapy Advisor take:
According to a new study published in the Annals of Oncology, the randomized phase 1/2 POSEIDON trial investigating the use of abituzumab combined with cetuximab and irinotecan for the treatment of patients with KRAS wild-type metastatic colorectal cancer did not meet its primary progression-free survival endpoint.
For the study, researchers sought to investigate abituzumab, a humanized monoclonal antibody that targets intregrins involved in tumor progression and metastasis. Patients with KRAS wild-type metastatic colorectal cancer who had progressed after oxaliplatin-containing therapy were randomly assigned to receive abituzumab 500mg every 2 weeks with cetuximab and irinotecan (arm A), abituzumab 1000mg every 2 weeks with cetuximab and irinotecan (arm B), or cetuximab and irinotecan alone (arm C).
The phase 1 portion of the study demonstrated abituzumab was safe at doses up to 1000mg. Results showed similar progression-free survival rates among all three arms in the phase 2 part.
The hazard ratio of arm A versus arm C was 1.13 (95% CI 0.78 - 1.64) and the hazard ratio of arm B compared with arm C was 1.11 (95% CI 0.77 - 1.61). Results showed similar response rates among all three arms, but researchers note that there was a trend toward improved overall survival in patients treated with abituzumab.
Abituzumab with cetuximab and irinotecan forcolorectal cancer did not meet primary endpoint.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed